Comparison of HIV-1 Derived Immunogens in Individuals with High CD4 Count for Prevention

Inclusion Criteria Concurrent Medication: Allowed: Short-term nonsteroidal anti-inflammatory therapy. Patients must have: HIV seropositivity. CD4 count >= 500 cells/mm3. Successful establishment of EBV-transformed B-cell lines at study entry. Consent of parent or guardian if < 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Suspected or known allergies to any vaccine components. Medical contraindication. Problem with compliance. Concurrent Medication: Excluded: Antiretroviral therapy (e.g., AZT, ddI, or ddC). Agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin). Parenteral therapies (including SC allergy sensitization). Other investigational HIV drugs or therapies. Prior Medication: Excluded: Any prior vaccinations against HIV. Antiretroviral therapy (e.g., AZT, ddI, or ddC) within the past 6 months. Agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin) within the past 3 months. Parenteral therapies (including SC allergy sensitization) within the past 3 months. Other investigational HIV drugs or therapies within the past 3 months.